EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study

Christina Zirou, Sentiljana Gumeni iD, Ioannis Bellos iD, Ioannis Ntanasis-Stathopoulos iD, Aimilia D Sklirou iD, Tina Bagratuni, Eleni Korompoki, Filia Apostolakou, Ioannis Papassotiriou iD, Ioannis P Trougakos iD, Evangelos Terpos iD

Viruses · 2023

DOI: 10.3390/v15112250 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Viruses, 2023. Verfasst von Christina Zirou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Sotiria General and Chest Diseases Hospital of Athens, 11527 Athens, Greece. Hauptthemen laut MEDLINE: Antibody Formation, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Severe coronavirus disease 19 (COVID-19) is characterized by a dysregulated inflammatory response, with humoral immunity playing a central role in the disease course. The objective of this study was to assess the immune response and the effects of vaccination in recovered individuals with variable disease severity up to one year following natural infection.

Methods

A prospective cohort study was conducted including patients with laboratory-confirmed COVID-19. Disease severity was classified as mild, moderate, and severe based on clinical presentation and outcomes. Anti-RBD (receptor binding domain) and neutralizing antibodies were evaluated at multiple timepoints during the first year after COVID-19 diagnosis.

Results

A total of 106 patients were included; of them, 28 were diagnosed with mild, 38 with moderate, and 40 with severe disease. At least one vaccine dose was administered in 58 individuals during the follow-up. Participants with mild disease presented significantly lower anti-RBD and neutralizing antibodies compared to those with moderate and severe disease up to the 3rd and 6th months after the infection, respectively. After adjusting for covariates, in the third month, severe COVID-19 was associated with significantly higher anti-RBD (β: 563.09; 95% confidence intervals (CI): 257.02 to 869.17) and neutralizing (β: 21.47; 95% CI: 12.04 to 30.90) antibodies. Among vaccinated individuals, at the 12th month, a history of moderate disease was associated with significantly higher anti-RBD levels (β: 5615.19; 95% CI: 657.92 to 10,572.46).

Conclusions

Severe COVID-19 is associated with higher anti-RBD and neutralizing antibodies up to 6 months after the infection. Vaccination of recovered patients is associated with a remarkable augmentation of antibody titers up to one year after COVID-19 diagnosis, regardless of disease severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibody FormationCOVID-19HumansCOVID-19 TestingProspective StudiesSARS-CoV-2Patient AcuityAntibodies, NeutralizingVaccinationAntibodies, Viral

Stichwörter der Autor:innen

COVID-19SARS-CoV-2antibodyimmune systemseverityvaccination

Substanzen

Antibodies, NeutralizingAntibodies, Viral

Autor:innen und Institutionen

  • Department of Internal Medicine, Sotiria General and Chest Diseases Hospital of Athens, 11527 Athens, Greece.
  • Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 15771 Athens, Greece.
  • Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
  • Department of Clinical Biochemistry, "Aghia Sophia" Children's Hospital, 11527 Athens, Greece.

ORCID-Profile: Sentiljana Gumeni, Ioannis Bellos, Ioannis Ntanasis-Stathopoulos, Aimilia D Sklirou, Ioannis Papassotiriou, Ioannis P Trougakos, Evangelos Terpos

Zitieren

APA

Zirou, C., Gumeni, S., Bellos, I., Ntanasis-Stathopoulos, I., Sklirou, A. D., Bagratuni, T., Korompoki, E., Apostolakou, F., Papassotiriou, I., Trougakos, I. P., & Terpos, E. (2023). Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study. Viruses. https://doi.org/10.3390/v15112250

Vancouver

Zirou C, Gumeni S, Bellos I, Ntanasis-Stathopoulos I, Sklirou AD, Bagratuni T, et al. Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study. Viruses. 2023. doi:10.3390/v15112250

BibTeX
@article{Zirou2023,
  author = {Zirou, Christina and Gumeni, Sentiljana and Bellos, Ioannis and Ntanasis-Stathopoulos, Ioannis and Sklirou, Aimilia D and Bagratuni, Tina and Korompoki, Eleni and Apostolakou, Filia and Papassotiriou, Ioannis and Trougakos, Ioannis P and Terpos, Evangelos},
  title = {Longitudinal Analysis of Antibody Response Following SARS-CoV-2 Infection Depending on Disease Severity: A Prospective Cohort Study},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15112250}
}
Kostenlos starten →